文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

吸入一氧化二氮治疗难治性抑郁症的2期试验

A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression.
PubMed 文献 · Sci Transl Med · 2021-01-01

这项2期交叉试验纳入24例重度难治性抑郁症患者,随机接受单次1小时吸入50%一氧化二氮、25%一氧化二氮或安慰剂。一氧化二氮较安慰剂显著改善抑郁症状(P=0.01),25%与50%浓度间无差异(P=0.58),且不良事件随剂量降低而明显减少。

要点

  • 25%与50%一氧化二氮改善难治性抑郁症疗效无显著差异。
  • 一氧化二氮较安慰剂显著改善抑郁症状(P=0.01)。
  • 不良事件随吸入浓度降低而明显减少(P<0.001)。

核心结论

  • 25%一氧化二氮改善难治性抑郁症的疗效与50%相当,且不良事件率明显更低。

研究设计与样本

  • 2期临床试验(NCT03283670),24例重度难治性抑郁症患者以交叉设计随机接受单次1小时吸入50%一氧化二氮、25%一氧化二氮或安慰剂(空气/氧气)。
  • 主要结局为汉密尔顿抑郁量表21项(HDRS-21)评分变化。

主要发现

  • 一氧化二氮较安慰剂显著改善抑郁症状(P=0.01),25%与50%一氧化二氮之间无差异(P=0.58)。
  • 25%与安慰剂估计差异:2小时-0.75分(P=0.73),24小时-1.41分(P=0.52),第1周-4.35分(P=0.05),第2周-5.19分(P=0.02)。
  • 50%与安慰剂估计差异:2小时-0.87分(P=0.69),24小时-1.93分(P=0.37),第1周-2.44分(P=0.25),第2周-7.00分(P=0.001)。
  • 不良事件随剂量明显减少(P<0.001)。

临床怎么用

  • 对难治性重度抑郁症患者,25%一氧化二氮吸入可能作为疗效与50%相当且不良事件更少的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nitrous oxide at 50% inhaled concentration has been shown to improve depressive symptoms in patients with treatment-resistant major depression (TRMD). Whether a lower concentration of 25% nitrous oxide provides similar efficacy and persistence of antidepressant effects while reducing the risk of adverse side effects is unknown. In this phase 2 clinical trial (NCT03283670), 24 patients with severe TRMD were randomly assigned in a crossover fashion to three treatments consisting of a single 1-hour inhalation with (i) 50% nitrous oxide, (ii) 25% nitrous oxide, or (iii) placebo (air/oxygen). The primary outcome was the change on the Hamilton Depression Rating Scale (HDRS-21). Whereas nitrous oxide significantly improved depressive symptoms versus placebo (P = 0.01), there was no difference between 25 and 50% nitrous oxide (P = 0.58). The estimated differences between 25% and placebo were -0.75 points on the HDRS-21 at 2 hours (P = 0.73), -1.41 points at 24 hours (P = 0.52), -4.35 points at week 1 (P = 0.05), and -5.19 points at week 2 (P = 0.02), and the estimated differences between 50% and placebo were -0.87 points at 2 hours (P = 0.69), -1.93 points at 24 hours (P = 0.37), -2.44 points at week 1 (P = 0.25), and -7.00 points at week 2 (P = 0.001). Adverse events declined substantially with dose (P < 0.001). These results suggest that 25% nitrous oxide has comparable efficacy to 50% nitrous oxide in improving TRMD but with a markedly lower rate of adverse effects.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Nagele P, Palanca BJ, Gott B, et al. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med. 2021. PMID: 34108247. doi:10.1126/scitranslmed.abe1376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。